66Colin is a recognized expert in medical imaging and has spent much of his recent career acting as a medical imaging consultant to biotech and pharma companies developing novel pharmaceuticals. Colin joined Alacrita from BioClinica, where he had provided medical imaging consulting services and served on number of Advisory Boards, including bone safety for Rosiglitazone and Canagliflozin. His consulting activities have spanned small molecules, biologics and medical devices and has supported several PMAs.
Colin has shared his expertise as a contributing author for over 60 medical imaging publications in leading scientific journals. He is co-author of several books including Clinical Trials in Osteoporosis and Clinical Trials in Rheumatoid Arthritis and Osteoarthritis. His latest book, Medical Imaging in Clinical Trials, was published by Springer in February of 2014.
Colin has spent the more than the last 25 years working in the pharmaceutical, device and biopharmaceutical services organizations. After his PhD he worked at Syntex Research, Europe and then moved to Procter & Gamble Pharmaceuticals. He moved from the UK to the USA in 1994 to create Bona Fide Ltd., a new start-up medical imaging service organization for a devices company: Lunar Corporation (now part of GE). 5 years later Bona Fide was sold to BioClinica (previously Bio-Imaging Technologies). Colin served as an officer of the company for 5 years while it was a publically held on the NASDAQ and was served in several roles including Senior Vice President of Medical Affairs and also Strategic Development.
Colin obtained his Bachelor’s degree from the University of Sheffield in the UK and his PhD from the University of Hull in the Ultrasonic assessment of bone. He is a chartered scientist and a Fellow of the Institute of Physics and Engineering in Medicine and also a Fellow of the Institute of Clinical Research in the UK. He is an aviator and holds a pilot’s license.